AntibodyLimited DatastaleWest China HospitalPhase 2
Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)
Cancer of Biliary Duct · EGFR
#EGFR#Antibody#Phase2#monoclonal-antibody#CancerofBiliaryDuct+1
Trials 1Status Recruiting